Skip to main navigation Skip to search Skip to main content

Network Pharmacology with Experimental Investigation of the Mechanisms of Rhizoma Polygonati against Prostate Cancer with Additional Herbzymatic Activity

  • Bexultan Kazybay
  • , Qinglei Sun
  • , Kanat Dukenbayev
  • , Ayan Amantaiuly Nurkesh
  • , Na Xu
  • , Aidana Kutzhanova
  • , Madina Razbekova
  • , Anar Kabylda
  • , Qing Yang
  • , Qian Wang
  • , Cuiping Ma
  • , Yingqiu Xie
  • Nazarbayev University
  • Qilu University of Technology
  • Shandong Taishanghuangjing Biotechnology Co. Ltd.
  • Qingdao University of Science and Technology

Research output: Contribution to journalArticlepeer-review

Abstract

A combination therapy of RhizomaPolygonati (RP) with goji (Lycium chinense) has earned a long history in the prescriptions to promote male health. However, the mechanisms at both molecular and nanoscale quantum levels are unclear. Here, we found that processed RP extract induces apoptosis and cell cycle arrest in cancer cells, thereby inhibiting prostate cancer cell proliferation enhanced by processed goji extract associated with an augment of the nanoscale herbzyme of phosphatase. For network pharmacology analysis, RP-induced PI3K-AKT pathways are essential for both benign prostatic hyperplasia and prostate cancer, and the RP/goji combination induces potent pathways which include androgen and estrogen response, kinase regulation, apoptosis, and prostate cancer singling. In addition, the experimental investigation showed that the prostate cancer cells are sensitive to RP extract for inhibiting colony formation. Finally, the natural compound baicalein found in RP ingredients showed a linked activity of top-ranked signaling targets of kinases including MAPK, AKT, and EGFR by the database of cMAP and HERB. Thus, both the nanozyme and ingredients might contribute to the RP in anti-prostate cancer which can be enhanced by goji extract. The proposed nanoscale RP extract might be of significance in developing novel anti-prostate cancer agents by combining goji compositions and targeted therapy compounds.

Original languageEnglish
JournalACS Omega
DOIs
Publication statusAccepted/In press - 2021

Funding

This work was supported from the Nazarbayev University Faculty-Development Competitive Research Grants Program [grant number 16797152 (15798117), that is, ID 110119FD4531, and grant number 16796808 (15874919), that is, ID 110119FD4542 to Y.X. as PI or Co-PI] and Shandong Taishanghuangjing Biotechnology Co. Ltd (Previously named as Taian Xianlu Food Co. Ltd). The authors would like to thank Prof. Xugang Li, who analyzed data with additional comments; Andrey Tsoy for kind support with the use of the Muse cell analyzer; and students including Aigerim Kabulova, Saltanat Kaldar, and Aigerim Nugmanova for kind help. The authors thank the Nazarbayev University FDCRG Program with grant number 16797152 (15798117, i.e., ID 110119FD4531) and grant number 16796808 (15874919, i.e., ID 110119FD4542).

ASJC Scopus subject areas

  • General Chemistry
  • General Chemical Engineering

Fingerprint

Dive into the research topics of 'Network Pharmacology with Experimental Investigation of the Mechanisms of Rhizoma Polygonati against Prostate Cancer with Additional Herbzymatic Activity'. Together they form a unique fingerprint.

Cite this